Answer
Recent approaches emphasize earlier, biomarker-confirmed treatment with anti-amyloid monoclonal antibodies (lecanemab and donanemab), while tau-targeting therapies, antisense oligonucleotides, GLP-1 receptor agonists, and other disease-modifying strategies are among the most actively studied next-generation approaches.
Current evidence
Two anti-amyloid monoclonal antibodies have received regulatory approval in the United States: lecanemab and donanemab. In the phase 3 Clarity AD trial, lecanemab reduced cognitive decline by 27% over 18 months compared with placebo, but was associated with amyloid-related imaging abnormalities (ARIA). Donanemab similarly slowed decline in early symptomatic Alzheimer's disease in the TRAILBLAZER-ALZ 2 trial. These results have shifted practice toward treating patients with biomarker-confirmed early disease and monitoring for ARIA. Beyond amyloid, tau-targeting approaches are advancing: an antisense oligonucleotide targeting tau mRNA (BIIB080/MAPTRx) reduced tau protein in cerebrospinal fluid in a phase 1b trial. Active and passive tau immunotherapies are also in clinical development. GLP-1 receptor agonists, originally developed for diabetes and obesity, are being tested in Alzheimer's disease because of links between metabolic dysfunction and neurodegeneration. Blood-based biomarkers such as plasma p-tau217 are increasingly used to identify eligible patients and monitor treatment effects.
Limitations
Despite these advances, the clinical effects of approved anti-amyloid antibodies are modest, and ARIA, including brain edema and microhemorrhages, requires MRI monitoring and can be serious. Many tau and metabolic therapies remain experimental, with phase 2 or early-phase data only, and some trials have failed to meet primary endpoints. Blood biomarker tests are not yet universally standardized, and access to PET or CSF confirmation remains uneven.
What this means
These developments are likely to reinforce a precision-medicine model: patients with biomarker-confirmed Alzheimer's disease may be treated earlier, with careful risk stratification for ARIA. Future progress may depend on combination therapies that target both amyloid and tau, as well as on scalable blood-based biomarkers to make trials and clinical care more inclusive.
EvidenceSources (9)
Last checked 2026-09-20Source details
Sources (9)
Confidence is an AI estimate, not an independent assessment of source quality.
- FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval
U.S. Food and Drug Administration · 2023-07-06
Reputable websiteAI confidence: 95% - FDA Approves Treatment for Adults with Alzheimer's Disease
U.S. Food and Drug Administration · 2024-07-02
Reputable websiteAI confidence: 90% - Alzheimer's disease drug development pipeline: 2024
Cummings J, et al. · 2024-04-25
Peer reviewedAI confidence: 85% - Lecanemab in Early Alzheimer's Disease
van Dyck CH, et al. · 2023-01-05
Peer reviewedAI confidence: 98% - Donanemab in Early Symptomatic Alzheimer Disease
Sims JR, et al. · 2023-07-17
Peer reviewedAI confidence: 95% - Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial
Mummery CJ, et al. · 2023-05-22
Peer reviewedAI confidence: 90% - AADvac1, an active vaccine against tau, in mild Alzheimer's disease: a randomised, double-blind, placebo-controlled phase 2 trial
Novak P, et al. · 2021-04-22
Peer reviewedAI confidence: 85% - A Research Study to Compare Semaglutide to Placebo in People With Early Alzheimer's Disease (EVOKE)
ClinicalTrials.gov, National Library of Medicine · 2021-03-15
Reputable websiteAI confidence: 80% - The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
Hansson O, et al. · 2022-04-22
GuidelineAI confidence: 90%
Update history
- Initial answerVersion 1Initial generation summarizing recent Alzheimer's treatment approaches as of September 2026.9 sources · AI-generated